Celltrion: Profit Recovery Reflected in Trailing Numbers, Shares Below 52-Week High

Celltrion's trailing twelve-month operating margin is 31.7% on revenue of ₩4.9T, and the shares closed at ₩180,400 on 2026-10-12, about 28.1% below the 52-week high of ₩251,000. Recent filings show repeated share buybacks and a share cancellation decision, while investor flow and short-selling data are not available.

Written Oct 13, 2026 · Data as of Oct 12, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

X f WA TG r/in @

Thesis

The data supports a clear earnings recovery. Operating income rose from ₩492.0B in 2024 to ₩1.2T in 2025, and the trailing figure to H1 2026 is ₩1.6T. Free cash flow of ₩823.1B and a liabilities-to-equity ratio of 31.3% point to a sound financial position.

What the data does not settle is how durable this is. Margins have swung widely over five years, from 39.6% in 2021 to 13.8% in 2024 and 31.7% now. ROE of 8.9% remains below the 13.4% to 14.8% seen in 2021 and 2022. Preliminary consolidated earnings were filed on 2026-10-12, but their figures are not included in the data provided. Price returns have been modest: 1.2% over one month, 3.0% over three months and 3.9% over one year.

Business overview

Celltrion is a KOSPI-listed company in the Biotech & Pharma sector, founded on 1991-02-27 and listed on 2018-02-09. It has 230,939,154 listed shares and a market capitalization of about ₩41.7T. The CEOs are listed as 기우성 and 서진석. Revenue has grown from ₩1.9T in 2021 to ₩4.2T in 2025, with a dip of 4.7% in 2023 and a jump of 63.4% in 2024. The data does not describe products or segments.

Every earlier JONBUR Research report and update note on Celltrion, with Pro.

Unlock with Pro

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

Source: KRX statistical information